TY - JOUR
T1 - Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score
AU - PROTECT investigators
AU - Jimenez, David
AU - Lobo, Jose Luis
AU - Fernandez-Golfin, Covadonga
AU - Portillo, Ana K.
AU - Nieto, Rosa
AU - Lankeit, Mareike
AU - Konstantinides, Stavros
AU - Prandoni, Paolo
AU - Muriel, Alfonso
AU - Yusen, Roger D.
N1 - Publisher Copyright:
© Schattauer 2016.
PY - 2016/4
Y1 - 2016/4
N2 - The prognostic value of the European Society of Cardiology (ESC) 2014 algorithm and the Bova score has lacked adequate validation. According to the ESC 2014 guidelines and the Bova score, we retrospectively risk stratified normotensive patients with PE who were enrolled in the PROTECT study. This study used a complicated course (which consisted of death from any cause, haemodynamic collapse, or recurrent PE) as the primary endpoint, and follow-up occurred through 30 days after the PE diagnosis. Of 848 patients, 37% had a sPESI of 0 and 5 (1.6%; 95% confidence interval [CI], 0.5–3.7%) experienced a complicated course. Of 143 patients with a sPESI of 0 points and negative computed tomographic pulmonary angiography (CTPA) for right ventricle (RV) dysfunction, three (2.1%; 95% CI, 0.4–6.0%) experienced a complicated course. Four hundred seventy-eight (56%) patients with a sPESI ≥ 1 had echocardiographic evidence of RV dys function or elevated troponin level or none, and 48 (10%, 95% CI, 7.5–13.1%) experienced a complicated course. Fifty-seven (6.7%) patients with a sPESI ≥ 1 had echocardiographic RV dysfunction and elevated troponin level, and 10 (17.5%; 95% CI, 8.8–29.9%) experienced a complicated course, compared to 21.6% (8 of 37 patients, 21.6%; 95% CI, 9.8–38.2%) in Bova risk class III. In conclusion, the ESC 2014 prognostic algorithm is effective in the risk stratification of normotensive patients with PE. Use of CTPA did not improve the ability for identification of low-risk PE. Bova risk scoring did not significantly improve identification of intermediate-high risk PE.
AB - The prognostic value of the European Society of Cardiology (ESC) 2014 algorithm and the Bova score has lacked adequate validation. According to the ESC 2014 guidelines and the Bova score, we retrospectively risk stratified normotensive patients with PE who were enrolled in the PROTECT study. This study used a complicated course (which consisted of death from any cause, haemodynamic collapse, or recurrent PE) as the primary endpoint, and follow-up occurred through 30 days after the PE diagnosis. Of 848 patients, 37% had a sPESI of 0 and 5 (1.6%; 95% confidence interval [CI], 0.5–3.7%) experienced a complicated course. Of 143 patients with a sPESI of 0 points and negative computed tomographic pulmonary angiography (CTPA) for right ventricle (RV) dysfunction, three (2.1%; 95% CI, 0.4–6.0%) experienced a complicated course. Four hundred seventy-eight (56%) patients with a sPESI ≥ 1 had echocardiographic evidence of RV dys function or elevated troponin level or none, and 48 (10%, 95% CI, 7.5–13.1%) experienced a complicated course. Fifty-seven (6.7%) patients with a sPESI ≥ 1 had echocardiographic RV dysfunction and elevated troponin level, and 10 (17.5%; 95% CI, 8.8–29.9%) experienced a complicated course, compared to 21.6% (8 of 37 patients, 21.6%; 95% CI, 9.8–38.2%) in Bova risk class III. In conclusion, the ESC 2014 prognostic algorithm is effective in the risk stratification of normotensive patients with PE. Use of CTPA did not improve the ability for identification of low-risk PE. Bova risk scoring did not significantly improve identification of intermediate-high risk PE.
KW - Biomarkers
KW - Clinical scores
KW - Echocardiography
KW - Prognosis
KW - Pulmonary embolism
UR - http://www.scopus.com/inward/record.url?scp=84964766195&partnerID=8YFLogxK
U2 - 10.1160/TH15-09-0761
DO - 10.1160/TH15-09-0761
M3 - Article
C2 - 26738514
AN - SCOPUS:84964766195
SN - 0340-6245
VL - 115
SP - 827
EP - 834
JO - Thrombosis and haemostasis
JF - Thrombosis and haemostasis
IS - 4
ER -